Johnson & Johnson (JNJ) Stock

Johnson & Johnson (JNJ) is a Healthcare stock trading at $263.40 (as of 2026-07-24), with a market capitalization of $634.77B and a trailing P/E of 30.2. Figures are sourced from first-party U.S. SEC EDGAR filings and market data.

Johnson & Johnson and its subsidiaries operate in healthcare, developing, manufacturing, and selling products worldwide. Its remaining activities are organized around Innovative Medicine for prescription therapies, and MedTech for medical devices and related solutions, serving hospitals, healthcare professionals, wholesalers, and retailers.

Understand Johnson & Johnson: how it makes money

Johnson & Johnson researches, develops, manufactures, and sells healthcare products worldwide, with profit tied to selling prescription products in its Innovative Medicine segment and medical technologies in its MedTech segment, after it separated its Consumer Health business into Kenvue in 2023.

JNJ’s current profit model is concentrated in two remaining reportable segments, Innovative Medicine and MedTech, because Consumer Health brands were separated into Kenvue in 2023.

Revenue by segment (latest quarter)
Innovative Med$15.8B
MedTech$8.8B

Business quality (Solid): Clear segment structure is available for Innovative Medicine and MedTech, but operational KPIs and risks are limited to the provided segment and business description facts.

Valuation: At 26× earnings, JNJ trades 57% above the Pharmaceutical Products average (17×). Note: one-time items can distort reported P/E.

Bull case

  • Focused portfolio after the Consumer Health separation: JNJ strategically separated its Consumer Health business into Kenvue in 2023, leaving JNJ focused on higher-growth, innovation-driven segments.
  • Segment revenue visibility: The company provides reported sales for both Innovative Medicine and MedTech, which helps investors track where company-level performance is coming from.

Bear case

  • Reduced exposure to Consumer Health brands at JNJ: TYLENOL, LISTERINE, and BAND-AID are now owned by Kenvue, so JNJ does not directly participate in that Consumer Health revenue stream.
  • Potential dependence on Innovative Medicine and MedTech: With the current structure concentrated in Innovative Medicine and MedTech, unfavorable developments affecting either segment could be more impactful than under a broader multi-segment mix.
Valuation — source: SEC EDGAR (first-party)
Price$263.40
Market Cap$634.77B
P/E Ratio30.2
EV / EBITDA20.0
Price / Book7.47
Price / Sales6.48
FCF Yield3.2%
DCF Value (model)$148.56
DCF Upside vs Price-43.6%
Profitability & Growth — source: SEC EDGAR
Revenue (TTM)$94.19B
Net Margin28.5%
Revenue Growth (YoY)6.6%
EPS Growth (YoY)0.0%
FCF Growth (YoY)41.0%
Financial Health — source: SEC EDGAR
Altman Z-Score5.45 (safe)
Piotroski F-Score3/9 (weak)
Valuation vs Sector & Industry
Stock P/E30.2
Sector P/E (Healthcare)21.2
Industry P/E (Pharmaceutical Products)17.0
vs Sector42.1%
vs Industry77.9%
Smart-Money Activity — SEC Form 4 / 13F / Congressional disclosures
Insider Buys (12mo)1
Insider Sells (12mo)2
Top Institutional HolderBlackRock, Inc. ($52.16B)
Institutional Holders Tracked10
Congressional Trades (recent)10
Company
SectorHealthcare
IndustryPharmaceutical Products
CEOJoaquin Duato
Employees138,100
CountryUS
IPO Date1943-01-02

Related Companies (Business model: Big Pharma / Branded Drugs + Medical Devices / Life Science Tools; 8 closest by market cap; US-domiciled)

  • Eli Lilly and Company (LLY)
  • AbbVie Inc. (ABBV)
  • Merck & Co., Inc. (MRK)
  • Abbott Laboratories (ABT)
  • Pfizer Inc. (PFE)
  • Bristol-Myers Squibb Company (BMY)
  • Vertex Pharmaceuticals Incorporated (VRTX)
  • Regeneron Pharmaceuticals, Inc. (REGN)
JNJ earnings history · JNJ institutional & insider holders · JNJ KPIs & operating metrics · Congress trades · Insider trades · Short interest · Stock screener

Data as of 2026-07-24.

Figures sourced from U.S. Securities and Exchange Commission (SEC EDGAR) filings and market data. Not personalized investment advice.